Cardinal Health Q1 FY23 revenue up 13% to $49.6B; GAAP EPS $0.40, non-GAAP EPS $1.20; Medical segment posts loss

CARDINAL HEALTH INC

2023-Q1 EPS reported $0.40 revenue$49,603,000,000

GAAP operating earnings $137M, including $154M goodwill impairment; GAAP diluted EPS $0.40, down 57% YoY.
Non-GAAP operating earnings $423M (-20% YoY); non-GAAP diluted EPS $1.20 (-7% YoY).
Pharmaceutical segment profit up 6% to $431M; Medical segment loss of $8M vs $123M profit prior year.
Revised FY23 Medical segment profit outlook to flat to 20% decline; reaffirms non-GAAP EPS guidance $5.05-$5.40.
Updated FY23 interest/other expense to $140M-$160M, non-GAAP tax rate 23%-24%, diluted shares ~262-264M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CARDINAL HEALTH INC reported the quarter ended September 30, 2022 results: revenue $49.6 billion, net income $110 million, EPS $0.40. Guidance reaffirmed.

Period: the quarter ended September 30, 2022
Revenue: $49.6 billion
Net income: $110 million
EPS: $0.40
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Cardinal Health Reports First Quarter Fiscal 2023 Results • Revenue increased 13% to $49.6 billion • GAAP 1 operating earnings were $137 million, GAAP diluted EPS were $0.40 • Non-GAAP operating earnings decreased 20% to $423 million due to a decline in Medical segment profit, partially offset by an increase in Pharmaceutical segment profit; non-GAAP diluted EPS decreased 7% to $1.20 • Company reaffirmed fiscal year 2023 non-GAAP EPS guidance

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

CARDINAL HEALTH INC filing history →

Source: SEC EDGAR

accession 0000721371-22-000131

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.